PCRX · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$36.460.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
Pacira Biosciences, Inc.’s own guidance, from its results release of August 4, 2026. It is the company’s statement of what it expects, not a forecast of ours.
As the company names it — a part of revenue, not the total.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $176.7M | $179.5M | -1.59% |
| Profit | $28.5M | $5.4M | +425.06% |
| Profit per share | $0.70 | $0.12 | +483.33% |
| Free Cash Flow | $46.4M | $57M | -18.47% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Pacira Biosciences, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The first half of 2026 was marked by solid revenue growth and strong execution of our 5x30 strategy across the business,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has two commercial-stage non-opioid treatments: EXPAREL ® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management and ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies. Its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), is a novel, locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Pacira Biosciences, Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.